{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:39:13Z","timestamp":1781890753496,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.eururo.2005.11.006","type":"journal-article","created":{"date-parts":[[2005,12,23]],"date-time":"2005-12-23T07:13:55Z","timestamp":1135322035000},"page":"519-527","source":"Crossref","is-referenced-by-count":62,"title":["Cost-Consequence Analysis Evaluating the Use of Botulinum Neurotoxin-A in Patients with Detrusor Overactivity Based on Clinical Outcomes Observed at a Single UK Centre"],"prefix":"10.1016","volume":"49","author":[{"given":"Vinay","family":"Kalsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni B.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac A.O.","family":"Odeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheir","family":"Elneil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare J.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prokar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2005.11.006_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.ju.0000132152.53532.5d","article-title":"Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study","volume":"172","author":"Giannantoni","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.urology.2004.08.016","article-title":"Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra","volume":"65","author":"Smith","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2005.11.006_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib6","first-page":"2543","article-title":"Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results","volume":"12","author":"Hajebrahimi","year":"2005","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.urology.2004.01.041","article-title":"Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience","volume":"63","author":"Rapp","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2005.11.006_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2005.11.006_bib9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1097\/01.ju.0000143889.00681.3f","article-title":"The effect of botulinum-a toxin on patients with severe urge urinary incontinence","volume":"172","author":"Flynn","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib10","first-page":"249","article-title":"One surgeon\u2019s experience in 50 patients with botulinum toxin injection into the bladder and urethra (Abstract)","volume":"167","author":"Chancellor","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.sc.3101593","article-title":"Electromotive drug administration of lidocaine to anesthetize the bladder before botulinum-A toxin injections into the detrusor","volume":"42","author":"Schurch","year":"2004","journal-title":"Spinal Cord"},{"key":"10.1016\/j.eururo.2005.11.006_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","article-title":"A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin","volume":"174","author":"Popat","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib13","unstructured":"Werner M, Schmid D, Schurch B, Schuessler B. Efficacy of botulinum-A toxin in the treatment of refractory overactive bladder syndrome: preliminary results of a prospective non-randomized study. Non-discussion paper presented at the 2004 International Continence Society Congress, Paris 2004."},{"key":"10.1016\/j.eururo.2005.11.006_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1464-410X.2003.04312.x","article-title":"A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity","volume":"92","author":"Harper","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2005.11.006_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2005.11.006_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2005.11.006_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1464-410X.2000.00097.x","article-title":"Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin","volume":"86","author":"Rovner","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2005.11.006_bib18","first-page":"S11","article-title":"Treatment of the overactive bladder: Where we stand in 2003","volume":"5","author":"Dmochowski","year":"2003","journal-title":"Rev in Urol"},{"key":"10.1016\/j.eururo.2005.11.006_bib19","unstructured":"Swinscow TDV, Revised by Campbell MJ. Survival analysis. In: Statistics at Square One. Ninth ed. London: BMJ Publishing Group (http:\/\/bmj.bmjjournals.com\/collections\/statsbk\/index.shtml), 1997."},{"key":"10.1016\/j.eururo.2005.11.006_bib20","series-title":"Guide to the methods of technology appraisal","author":"National Institute for Clinical Excellence","year":"2004"},{"key":"10.1016\/j.eururo.2005.11.006_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bmj.319.7214.914","article-title":"Economic notes. Discounting","volume":"319","author":"Torgerson","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2005.11.006_bib22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.eururo.2005.11.006_bib23","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/S0149-2918(01)80156-9","article-title":"Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective","volume":"23","author":"O\u2019Brien","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2005.11.006_bib24","series-title":"Unit Costs of Health and Social Care 2004","author":"Curtis","year":"2004"},{"key":"10.1016\/j.eururo.2005.11.006_bib25","unstructured":"Department of Health. NHS Reference costs Appendix 1 NHS trusts (http:\/\/www.dh.gov.uk\/Home\/fs\/en). In: DOH, 2004."},{"key":"10.1016\/j.eururo.2005.11.006_bib26","unstructured":"British Medical Association. British National Formulary (BNF), No. 49. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, March 2005."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805007785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805007785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T05:55:46Z","timestamp":1547877346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283805007785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0302283805007785"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2005.11.006","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}